Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TQB2825 injection combined with chemotherapy in relapsed/refractory diffuse large B-cell lymphoma
CTR20250307Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Mar 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tqb2825 in diffuse large B-cell lymphoma (DLBCL), sponsored by Nanjing Shunxin Pharmaceutical. Started Mar 2025; status: active.
02
Drugs
tqb2825
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20250307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250307.